ArticleBreast cancer research and treatment2026
The impact of the COVID-19 pandemic on breast cancer screening, treatment, and overall survival.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeWe examined the association between the COVID-19 pandemic and screening, treatment, and overall survival for individuals diagnosed with breast cancer in Manitoba, Canada.
methodsWe used population-based data and a quasi-experimental study with an interrupted time series analysis to examine the number of screening mammograms, first treatment rates, and 2-year overall survival prior to and after COVID-19 for individuals diagnosed with breast cancer.
resultsThere was a significant decrease in screening mammograms 2 years after the start of the pandemic (ratio = 0.73%, 95% Confidence Interval (CI) 0.58, 0.89). From April to June 2020, fewer individuals diagnosed with stage I-III breast cancer had surgery (ratio = 0.59, 95% CI 0.33, 1.07). Fewer individuals diagnosed with stage I-III breast cancer had radiotherapy (RT) (ratio = 0.69, 95% CI 0.53, 0.91). RT factions per person-year were lower (ratio = 0.81, 95% CI 0.71, 0.92, April to June 2020 and 0.60, 95% CI 0.56, 0.66, July 2020 to December 2022). The proportion of individuals with stage I-III ER+ /HER2- breast cancer who had hormone therapy (HT) was lower (ratio = 0.55, 95% CI 0.36, 0.84). The proportion of individuals with stage I-III HER2+ breast cancer who had neoadjuvant chemotherapy (ratio = 3.64, 95% CI 1.18, 11.16) or targeted therapy (ratio = 3.34, 95% CI 1.13, 9.84) was higher. The proportion of individuals who had adjuvant chemotherapy (ratio = 0.14, 95% CI 0.04, 0.47, April to June 2020 and ratio = 0.19, 95% CI 0.08, 0.48, January to December 2022), targeted therapy (ratio = 0.14, 95% CI 0.04, 0.45, April to June 2020 and ratio = 0.18, 95% CI 0.07, 0.45 January to December 2022), or HT (ratio = 0.43, 95% CI 0.22, 0.83) was lower. The proportion of individuals with stage I-III triple-negative breast cancer who had neoadjuvant chemotherapy was higher (ratio = 2.92, 95% CI 1.04, 8.17). There was no difference for any treatment for stage IV breast cancers. There was no difference in 2-year overall survival for stage I-III or stage IV breast cancers.
conclusionIn Manitoba, Canada, there was a significant decrease in the number of screening mammograms 2 years after the start of the pandemic. Breast cancer treatment changed in accordance with updated guidelines with no impact on 2-year overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.